Reported Earnings • May 31
Full year 2026 earnings released: ₹3.05 loss per share (vs ₹5.03 loss in FY 2025) Full year 2026 results: ₹3.05 loss per share (improved from ₹5.03 loss in FY 2025). Revenue: ₹142.7m (down 40% from FY 2025). Net loss: ₹30.8m (loss narrowed 39% from FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Duyuru • May 26
Decipher Labs Limited to Report Q4, 2026 Results on May 30, 2026 Decipher Labs Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026 Reported Earnings • Feb 14
Third quarter 2026 earnings released: ₹0.53 loss per share (vs ₹0.59 loss in 3Q 2025) Third quarter 2026 results: ₹0.53 loss per share (improved from ₹0.59 loss in 3Q 2025). Revenue: ₹32.3m (down 46% from 3Q 2025). Net loss: ₹5.39m (loss narrowed 9.1% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 26% per year. Duyuru • Feb 09
Decipher Labs Limited to Report Q3, 2026 Results on Feb 12, 2026 Decipher Labs Limited announced that they will report Q3, 2026 results on Feb 12, 2026 New Risk • Dec 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹65m free cash flow). Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹105.5m market cap, or US$1.17m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Revenue is less than US$5m (₹176m revenue, or US$2.0m). Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹0.02 (vs ₹1.31 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹0.02 (up from ₹1.31 loss in 2Q 2025). Revenue: ₹43.3m (down 28% from 2Q 2025). Net income: ₹201.0k (up ₹13.5m from 2Q 2025). Profit margin: 0.5% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Duyuru • Nov 11
Decipher Labs Limited to Report Q2, 2026 Results on Nov 13, 2025 Decipher Labs Limited announced that they will report Q2, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025 Duyuru • Sep 08
Decipher Labs Limited, Annual General Meeting, Sep 30, 2025 Decipher Labs Limited, Annual General Meeting, Sep 30, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2026 earnings released: ₹3.39 loss per share (vs ₹0.94 profit in 1Q 2025) First quarter 2026 results: ₹3.39 loss per share (down from ₹0.94 profit in 1Q 2025). Revenue: ₹29.3m (down 61% from 1Q 2025). Net loss: ₹34.3m (down 462% from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance. Duyuru • Aug 12
Decipher Labs Limited to Report Q1, 2026 Results on Aug 14, 2025 Decipher Labs Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Reported Earnings • Jun 02
Full year 2025 earnings released: ₹5.03 loss per share (vs ₹1.66 loss in FY 2024) Full year 2025 results: ₹5.03 loss per share (further deteriorated from ₹1.66 loss in FY 2024). Revenue: ₹239.3m (down 34% from FY 2024). Net loss: ₹50.8m (loss widened 203% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 15
Third quarter 2025 earnings released: ₹0.59 loss per share (vs ₹0.01 profit in 3Q 2024) Third quarter 2025 results: ₹0.59 loss per share (down from ₹0.01 profit in 3Q 2024). Revenue: ₹59.7m (down 28% from 3Q 2024). Net loss: ₹5.93m (down ₹6.03m from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance. Duyuru • Jan 02
Decipher Labs Limited Appoints Preeti Singh as Company Secretary and Compliance Officer, with Effect from January 01, 2025 The board of directors of Decipher Labs Limited at its meeting held on 31 December, 2024, Appointment of Ms. Preeti Singh as the Company Secretary and Compliance Officer of the Company with effect from January 01, 2025. Ms. Preeti Singh is a qualified Company Secretary and legal professional. She is having rich experience in Secretarial and legal works for 3 years. Reported Earnings • Nov 16
Second quarter 2025 earnings released: ₹1.31 loss per share (vs ₹1.92 loss in 2Q 2024) Second quarter 2025 results: ₹1.31 loss per share (improved from ₹1.92 loss in 2Q 2024). Revenue: ₹59.9m (down 20% from 2Q 2024). Net loss: ₹13.3m (loss narrowed 32% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Duyuru • Sep 26
Decipher Labs Limited Announces Executive Changes Decipher Labs Limited announced that the Mr. Siva Kumar Reddy Chappidi has resigned from the post of Company Secretary and Compliance Officer with effect from 30 September 2024 (post-closing hour) due to personal reasons. Mr. Sushant Mohan Lal, Executive Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer. Reported Earnings • Aug 20
First quarter 2025 earnings released: EPS: ₹0.94 (vs ₹0.94 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.94 (up from ₹0.94 loss in 1Q 2024). Revenue: ₹74.4m (down 22% from 1Q 2024). Net income: ₹9.47m (up ₹18.9m from 1Q 2024). Profit margin: 13% (up from net loss in 1Q 2024). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Duyuru • Aug 16
Decipher Labs Limited, Annual General Meeting, Sep 30, 2024 Decipher Labs Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time. Duyuru • Aug 09
Decipher Labs Limited to Report Q1, 2025 Results on Aug 14, 2024 Decipher Labs Limited announced that they will report Q1, 2025 results on Aug 14, 2024 New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.8% per year over the past 5 years. Market cap is less than US$10m (₹180.2m market cap, or US$2.16m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹351m revenue, or US$4.2m). New Risk • Feb 16
New major risk - Revenue and earnings growth Earnings have declined by 6.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.7% per year over the past 5 years. Market cap is less than US$10m (₹187.3m market cap, or US$2.26m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹280m revenue, or US$3.4m). Board Change • Oct 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Whole-Time Director Sushant Lal is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Sep 17
Decipher Labs Limited Announces Executive Changes Mudunuru Limited announced that Mr. Pankaj Tulsayani has resigned from the post of Company Secretary and Compliance Officer of Decipher Labs Limited with effect from September 16, 2023 (After close of business hours). Mr. Madhusudan Raju Mudunuru, Director of the Company will act as Compliance officer of the Company till the appointment of new Company Secretary and Compliance Officer. New Risk • Aug 17
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₹356m (US$4.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹159.4m market cap, or US$1.92m). Minor Risk Revenue is less than US$5m (₹356m revenue, or US$4.3m). Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹0.94 loss per share (vs ₹5.85 profit in 1Q 2023) First quarter 2024 results: ₹0.94 loss per share (down from ₹5.85 profit in 1Q 2023). Revenue: ₹95.1m (down 25% from 1Q 2023). Net loss: ₹9.48m (down 116% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Aug 08
Decipher Labs Limited to Report Q1, 2024 Results on Aug 14, 2023 Decipher Labs Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Duyuru • Jul 22
Decipher Labs Limited Announces Company Secretary and Compliance Officer Changes Decipher Labs Limited at its board meeting held on July 19, 2023, resignation of Ms. Megha Agarwal as Company Secretary and Compliance Officer of the Company effective June 30, 2023, appointment of Mr. Siva Kumar Reddy Chappidi as Company Secretary and Compliance Officer of the Company effective July 19, 2023. Mr. C. Siva Kumar Reddy is a qualified Company Secretary and is having working knowledge in Secretarial matters. Reported Earnings • Jun 01
Full year 2023 earnings released: ₹2.66 loss per share (vs ₹11.27 profit in FY 2022) Full year 2023 results: ₹2.66 loss per share (down from ₹11.27 profit in FY 2022). Revenue: ₹529.4m (down 19% from FY 2022). Net loss: ₹26.8m (down 124% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Feb 08
Decipher Labs Limited to Report Q3, 2023 Results on Feb 14, 2023 Decipher Labs Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 17% share price gain to ₹33.80, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹35.00, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 79% over the past three years. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 16% share price gain to ₹52.60, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 209% over the past three years. Duyuru • Aug 30
Decipher Labs Limited, Annual General Meeting, Sep 29, 2022 Decipher Labs Limited, Annual General Meeting, Sep 29, 2022, at 11:30 Indian Standard Time. Reported Earnings • Aug 18
First quarter 2023 earnings released: EPS: ₹5.85 (vs ₹0.66 in 1Q 2022) First quarter 2023 results: EPS: ₹5.85 (up from ₹0.66 in 1Q 2022). Revenue: ₹194.8m (up 45% from 1Q 2022). Net income: ₹59.1m (up ₹52.4m from 1Q 2022). Profit margin: 30% (up from 5.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improved over the past week After last week's 23% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years. Duyuru • Jul 30
Decipher Labs Limited to Report Q1, 2023 Results on Aug 13, 2022 Decipher Labs Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 13, 2022 Reported Earnings • May 18
Full year 2022 earnings released: EPS: ₹11.27 (vs ₹1.39 in FY 2021) Full year 2022 results: EPS: ₹11.27 (up from ₹1.39 in FY 2021). Revenue: ₹730.0m (up 31% from FY 2021). Net income: ₹113.8m (up ₹99.8m from FY 2021). Profit margin: 16% (up from 2.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹43.30, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 17% share price gain to ₹61.75, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 138% over the past three years. Recent Insider Transactions • Mar 21
CEO & Whole Time Director recently sold ₹421k worth of stock On the 16th of March, Janakiram Ajjarapu sold around 6k shares on-market at roughly ₹67.30 per share. This was the largest sale by an insider in the last 3 months. This was Janakiram's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹62.00, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 173% over the past three years. Reported Earnings • Feb 16
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹7.21 (up from ₹0.10 in 3Q 2021). Revenue: ₹210.2m (up 53% from 3Q 2021). Net income: ₹72.8m (up ₹71.8m from 3Q 2021). Profit margin: 35% (up from 0.8% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 20% share price decline to ₹61.05, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 194% over the past three years. Duyuru • Feb 04
Decipher Labs Limited to Report Q3, 2022 Results on Feb 14, 2022 Decipher Labs Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 19% share price gain to ₹81.90, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 301% over the past three years. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improved over the past week After last week's 57% share price gain to ₹59.95, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 153% over the past three years. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 22% share price gain to ₹36.60, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years. Reported Earnings • Jul 02
Full year 2021 earnings released The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹562.1m (up 134% from FY 2020). Net income: ₹14.0m (up 27% from FY 2020). Profit margin: 2.5% (down from 4.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improved over the past week After last week's 21% share price gain to ₹42.10, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improved over the past week After last week's 15% share price gain to ₹38.35, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 78% over the past three years. Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹31.80, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past three years. Reported Earnings • Feb 15
Third quarter 2021 earnings released: EPS ₹0.10 The company reported a decent third quarter result with improved revenues, although earnings and profit margins were weaker. Third quarter 2021 results: Revenue: ₹137.8m (up 270% from 3Q 2020). Net income: ₹1.04m (down 60% from 3Q 2020). Profit margin: 0.8% (down from 7.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 07
Decipher Labs Limited to Report Q3, 2021 Results on Feb 13, 2021 Decipher Labs Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 24% share price gain to ₹35.20, the stock is trading at a trailing P/E ratio of 26.6x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 76%. Is New 90 Day High Low • Dec 14
New 90-day high: ₹29.10 The company is up 29% from its price of ₹22.50 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Dec 08
Market bids up stock over the past week After last week's 15% share price gain to ₹28.85, the stock is trading at a trailing P/E ratio of 21.8x, up from the previous P/E ratio of 18.9x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%. Is New 90 Day High Low • Nov 23
New 90-day high: ₹26.05 The company is up 3.0% from its price of ₹25.25 on 25 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Valuation Update With 7 Day Price Move • Nov 20
Market bids up stock over the past week After last week's 15% share price gain to ₹24.85, the stock is trading at a trailing P/E ratio of 18.8x, up from the previous P/E ratio of 16.3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%. Reported Earnings • Nov 15
Second quarter 2021 earnings released: EPS ₹0.31 The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: ₹136.1m (up ₹123.8m from 2Q 2020). Net income: ₹3.09m (up ₹2.58m from 2Q 2020). Profit margin: 2.3% (down from 4.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 05
Decipher Labs Limited to Report Q2, 2021 Results on Nov 12, 2020 Decipher Labs Limited announced that they will report Q2, 2021 results on Nov 12, 2020 Duyuru • Oct 02
Decipher Labs Limited Approves Board Changes Decipher Labs Limited at its board meeting held on October 1, 2020 approved the appointment of the Promoter of the company Mr. Janakiram Ajjarapu as an Additional Director (Executive Director) and Key Managerial Person of the Company with effect from October 01, 2020. Further, in compliance with the circulars issued by BSE Limited, the company confirmed that Mr. Janakiram Ajjarapu has not been debarred from holding the office of Director by virtue of any SEBI order or any other authority. Also, he is not related to any Director or Key Managerial Personnel. The company further announced that Mr. Vasudev Kommaraju, Director of the company did not seek re-appointment in the Annual General meeting held on 29th September, 2020 and has ceased to be a Director of the company. Is New 90 Day High Low • Sep 24
New 90-day low: ₹19.20 The company is down 27% from its price of ₹26.25 on 26 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Duyuru • Aug 25
Decipher Labs Limited to Report Q1, 2021 Results on Sep 01, 2020 Decipher Labs Limited announced that they will report Q1, 2021 results on Sep 01, 2020 Duyuru • Jun 20
Decipher Labs Limited to Report Q4, 2020 Results on Jun 29, 2020 Decipher Labs Limited announced that they will report Q4, 2020 results on Jun 29, 2020